Antihypertensive drugs consist of a class of drugs that are primarily used in treating hypertension. Hypertension is a condition wherein the blood pressure in arteries is increased to persistently high value. High blood pressure also increases the risk associated with heart failure, and heart diseases stroke. Hypertension also leads to some of the other problems associated with renal impairment, visual impairment, and retinal haemorrhage.
According to study, “Antihypertensive Drugs Market by Therapeutic Class (Diuretics, ACE Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, and Others) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce, and Others Distribution Channel): Global Opportunity Analysis and Industry Forecast, 2019-2026”. Some of the key companies operating in the antihypertensive drugs market are Boehringer Ingelheim GmbH, Sanofi S.A., Johnson and Johnson, Merck KGaA, Bayer AG, Pfizer, Inc., AstraZeneca Plc., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Company, and Novartis International AG. The key players are enhancing the product portfolio, and business strategies to gain market share.
Based on therapeutic class, antihypertensive drugs market is segmented into diuretics, beta-adrenergic blockers, calcium channel blockers, Angiotensin Converting Enzyme (ACE) inhibitors, vasodilators, and others. Diuretics segment is further sub-segmented into loop diuretics, a thiazide diuretic, and potassium-sparing diuretics. The beta-blockers segment is also sub-segmented into beta-1 selective and intrinsic sympathomimetic. Calcium channel blockers hold a major share in the market owing to reduced side effects exhibited by drugs as compared to other antihypertensive drugs. However, the ACE inhibitors segment is further anticipated to depict significant growth over the forecast period. Some of the key benefits associated include a positive impact on overall health and a decrease in the progression of kidney diseases. Based on the condition, the market is segmented into primary hypertension and secondary hypertension. Based on medication type, the market is segmented into combination therapy, monotherapy, and fixed-dose combinations. In addition, based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and e-commerce.
The hospital segment held the largest share which is attributed to a rise in the number of hospitals globally. Furthermore, antihypertensive drugs are the prescription-based medications that are widely prescribed by healthcare experts available in hospitals further augmenting the growth of. The e-commerce segment is further expected to exhibit the highest growth over the forecast period, owing to a surge in the use of the internet globally.
The antihypertensive drugs market is driven by a surge in healthcare expenditure, followed by growth in geriatric population, increase in initiatives by private & government organizations and rise in the prevalence of hypertension across the globe. However, patent expirations of blockbuster drugs may impact the market.
Based on geography, the North-American region dominates the global antihypertensive drugs market owing to the easy availability of antihypertensive drugs and rise in incidence of hypertension in the region. Whereas, the Asian-Pacific and European regions are estimated to witness higher growth rate due to constantly evolving life science industry and a surge in awareness related to the use of antihypertensive drugs over the forecast period. The global antihypertensive the market accounted for the US $22,557 million in 2018 and is anticipated to reach the US $28,797 million by 2026, registering a CAGR of 3.1% from 2019-2026.
For More Information on the Research Report, refer to below links: –
Related Report: –
Contact Us: –
Ankur Gupta, Head Marketing & Communications